Editas Medicine appoints Gilmore O'Neill as President and CEO, effective June 1, 2022

Editas Medicine, Inc.

Gilmore O'Neill, former EVP of R&D at Sarepta, succeeds James Mullen as CEO; Mullen becomes Executive Chair.
O'Neill receives $625K base salary, 60% target bonus, and equity valued at ~$11M (options + RSUs + performance RSUs).
Mullen's base remains $655K through Dec 2022, then drops to $327.5K for part-time Executive Chair from Jan 2023.
O'Neill appointed to Board as class II director until 2024 annual meeting.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Gilmore O'Neill

President and Chief Executive Officer

EDIT · Editas Medicine, Inc.

Effective: 2022-06-01
Filed: April 14, 2022, 7:59 PM ET

On April 12, 2022, Editas Medicine, Inc. (the “Company”) appointed Gilmore O’Neill, M.B., M.M.Sc. as President and Chief Executive Officer of the Company, succeeding James C. Mullen as President and Chief Executive Officer of the Company, effective as of June 1, 2022 (the “Effective Date”).

Appointed

Gilmore O'Neill

director

EDIT · Editas Medicine, Inc.

Effective: 2022-06-01
Filed: April 14, 2022, 7:59 PM ET

Also on April 12, 2022, the Board, upon recommendation of the Board’s Nominating and Corporate Governance Committee, increased the size of the Board by one member and appointed Dr. O’Neill as a director, effective as of the Effective Date.

Role change

James C. Mullen

Executive Chair

EDIT · Editas Medicine, Inc.

Effective: 2022-06-01
Successor: Gilmore O'Neill
Filed: April 14, 2022, 7:59 PM ET

Mr. Mullen will continue to serve as Executive Chair of the Company’s Board of Directors (the “Board”).

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Gilmore O'Neill was appointed as President and Chief Executive Officer at Editas Medicine, Inc..

Action: appointed
Role: President and Chief Executive Officer

Exact text from the filing

On April 12, 2022, Editas Medicine, Inc. (the “Company”) appointed Gilmore O’Neill, M.B., M.M.Sc. as President and Chief Executive Officer of the Company, succeeding James C. Mullen as President and Chief Executive Officer of the Company, effective as of June 1, 2022 (the “Effective Date”).

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Gilmore O'Neill was appointed as director at Editas Medicine, Inc..

Action: appointed
Role: director

Exact text from the filing

Also on April 12, 2022, the Board, upon recommendation of the Board’s Nominating and Corporate Governance Committee, increased the size of the Board by one member and appointed Dr. O’Neill as a director, effective as of the Effective Date.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

James C. Mullen changed role as Executive Chair at Editas Medicine, Inc..

Action: will continue to serve as
Role: Executive Chair

Exact text from the filing

Mr. Mullen will continue to serve as Executive Chair of the Company’s Board of Directors (the “Board”).

View on SEC.gov

Editas Medicine, Inc. filing history →

Source: SEC EDGAR

accession 0001558370-22-005418

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.